[go: up one dir, main page]

ES2036221T3 - Procedimiento para preparar una composicion de l-dopa de dosis unitaria multiple. - Google Patents

Procedimiento para preparar una composicion de l-dopa de dosis unitaria multiple.

Info

Publication number
ES2036221T3
ES2036221T3 ES198787850251T ES87850251T ES2036221T3 ES 2036221 T3 ES2036221 T3 ES 2036221T3 ES 198787850251 T ES198787850251 T ES 198787850251T ES 87850251 T ES87850251 T ES 87850251T ES 2036221 T3 ES2036221 T3 ES 2036221T3
Authority
ES
Spain
Prior art keywords
dopa
preparing
procedure
unit dose
multiple unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787850251T
Other languages
English (en)
Inventor
Curt Henry Appelgren
Eva Christina Eskilsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asta Medica GmbH
Original Assignee
Asta Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Pharma AG filed Critical Asta Pharma AG
Application granted granted Critical
Publication of ES2036221T3 publication Critical patent/ES2036221T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A UNA DOSIS DE MULTIPLES UNIDADES QUE CONTIENE L-DOPA COMO EL COMPUESTO FARMACEUTICAMENTE ACTIVO, CON LO QUE LA COMPOSICION PROPORCIONA UNA LIBERACION DE L-DOPA SEGUN UN ENSAYO QUE CUMPLE LA NORMATIVA FARMACOPEA DE LOS ESTADOS UNIDOS EN UN JUGO GASTRICO ARTIFICIAL QUE TIENE UN PH MAXIMO DE 1,2 EN COMO MAXIMO UN 20% EN PESO DURANTE 1 HORA Y EN UN TAMPON DE FOSFATO SEGUN LA MISMA NORMATIVA UNA LIBERACION DE AL MENOS UN 35% EN PESO DURANTE 1 HORA Y AL MENOS UN 80% EN PESO DURANTE 3 HORAS.
ES198787850251T 1986-08-26 1987-08-21 Procedimiento para preparar una composicion de l-dopa de dosis unitaria multiple. Expired - Lifetime ES2036221T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8603582A SE460947B (sv) 1986-08-26 1986-08-26 En multiple-unit-dos komposition av l-dopa

Publications (1)

Publication Number Publication Date
ES2036221T3 true ES2036221T3 (es) 1993-05-16

Family

ID=20365397

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787850251T Expired - Lifetime ES2036221T3 (es) 1986-08-26 1987-08-21 Procedimiento para preparar una composicion de l-dopa de dosis unitaria multiple.

Country Status (15)

Country Link
US (1) US4981695A (es)
EP (1) EP0260236B1 (es)
JP (1) JPH0662405B2 (es)
AT (1) ATE58292T1 (es)
CA (1) CA1298198C (es)
DD (1) DD286107A5 (es)
DE (1) DE3766200D1 (es)
DK (1) DK442287A (es)
ES (1) ES2036221T3 (es)
FI (1) FI86689C (es)
HU (1) HU197211B (es)
MX (1) MX172918B (es)
NO (1) NO176549C (es)
PT (1) PT85591B (es)
SE (1) SE460947B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
CA2007055A1 (en) * 1989-01-06 1990-07-06 Garth Boehm Theophylline dosage form
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US7530461B2 (en) 1995-03-10 2009-05-12 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US6992107B1 (en) 1995-03-10 2006-01-31 Photocure Asa Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy
US6492420B2 (en) 1995-03-10 2002-12-10 Photocure As Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
US5997831A (en) * 1996-07-12 1999-12-07 Engelhard Corporation Method of catalytically treating the atmosphere and heat exchange devices produced thereby
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
MXPA04000775A (es) * 2001-07-26 2004-04-20 Merck Patent Ges Mit Baschrank Uso novedoso del 2 -[5-(4-fluorofenil) -3-piridilmetilamino-metil] -cromano y sus sales fisiologicamente aceptables.
CA2479218A1 (en) * 2002-03-21 2003-10-02 Martin C. Hinz Serotonin and catecholamine system segment optimization technology
ITMI20030827A1 (it) * 2003-04-18 2004-10-19 Unihart Corp Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
WO2005041926A1 (en) * 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid
AU2004296404A1 (en) * 2003-12-09 2005-06-23 Spherics, Inc. Bioadhesive polymers with catechol functionality
US20080311191A1 (en) * 2004-08-27 2008-12-18 Avinash Nangia Multi-Layer Tablets and Bioadhesive Dosage Forms
AU2006261893A1 (en) * 2005-06-23 2007-01-04 Combinatorx, Incorporated Improved dosage forms for movement disorder treatment
US20070275060A1 (en) * 2005-08-05 2007-11-29 Osmotica Costa Rica Sociedad Anonima Extended release solid pharmaceutical composition containing carbidopa and levodopa
US20090227673A1 (en) * 2006-01-13 2009-09-10 Bao Ting Zhu Method and Composition for the Treatment of Parkinson's Disease
EP2086515A2 (en) * 2006-03-02 2009-08-12 Vaunnex, Inc. Rate-controlled bioadhesive oral dosage formulations
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
AU2007338631A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1116256A (fr) * 1954-12-09 1956-05-07 Stylographe à bille
DE1128461B (de) * 1959-01-15 1962-04-26 Fernseh Gmbh Einrichtung zum Schutz einer Fernsehaufnahmeroehre gegen Fehl-bedienung ihrer motorisch angetriebenen Lichtstromregeleinrichtung
FR2116256A1 (en) * 1970-12-02 1972-07-13 Sobio Lab Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects
JPS5518694B2 (es) * 1973-04-02 1980-05-21
DE2343218C2 (de) * 1973-08-28 1986-08-07 Hoechst Ag, 6230 Frankfurt Furosemid enthaltende Pellets
DE2513940A1 (de) * 1975-03-29 1976-10-14 Merck Patent Gmbh Pharmazeutische zubereitung
DE2655331A1 (de) * 1976-12-07 1978-06-08 Hoechst Ag Zubereitungsformen von 3-n-pyrrolidino-4-phenoxy-5-sulfamyl-benzoesaeure und verfahren zu ihrer herstellung
JPS5436645A (en) * 1977-08-29 1979-03-17 Omron Tateisi Electronics Co Temperature control system for boiler
CH627077A5 (en) * 1978-01-01 1981-12-31 Sankyo Co Pharmaceutical composition which foams in the intestine
CH649216A5 (de) * 1979-08-16 1985-05-15 Sandoz Ag Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film.
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4446138A (en) * 1982-02-10 1984-05-01 Pack Howard M Method and composition for reducing weight
JPS59139317A (ja) * 1983-01-31 1984-08-10 Teisan Seiyaku Kk 持続性のニフエジピン製剤
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa

Also Published As

Publication number Publication date
NO873589L (no) 1988-02-29
PT85591A (en) 1987-09-01
SE8603582D0 (sv) 1986-08-26
MX172918B (es) 1994-01-21
SE460947B (sv) 1989-12-11
EP0260236B1 (en) 1990-11-14
FI86689C (fi) 1992-10-12
JPS63139128A (ja) 1988-06-10
NO873589D0 (no) 1987-08-25
EP0260236A1 (en) 1988-03-16
DK442287D0 (da) 1987-08-25
FI873672L (fi) 1988-02-27
HUT44438A (en) 1988-03-28
NO176549C (no) 1995-04-26
ATE58292T1 (de) 1990-11-15
SE8603582L (sv) 1988-02-27
PT85591B (pt) 1990-05-31
DK442287A (da) 1988-02-27
JPH0662405B2 (ja) 1994-08-17
FI873672A0 (fi) 1987-08-25
US4981695A (en) 1991-01-01
HU197211B (en) 1989-03-28
DD286107A5 (de) 1991-01-17
DE3766200D1 (de) 1990-12-20
NO176549B (no) 1995-01-16
FI86689B (fi) 1992-06-30
CA1298198C (en) 1992-03-31

Similar Documents

Publication Publication Date Title
ES2036221T3 (es) Procedimiento para preparar una composicion de l-dopa de dosis unitaria multiple.
ES2040261T3 (es) Procedimiento para preparar acidos 6-fluor-4-oxo-1,4-dihidroquinolina-3-carboxilicos sustituidos y acidos 9-fluor-3-metil-7-oxo-2,3-dihidro-7h-pirido(1,2,3-de)(1,4)benzoxazina-6-carboxilico sustituidos.
ES2094721T3 (es) Analogos de la camptotecina solubles en agua.
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
UY23835A1 (es) Procedimiento para la preparacion de compuesto de acilo
BG60102B2 (bg) Метод за получаване на 5-флуор-2(((4-циклопропил- метокси-2-пиридинил)метил)тионил)-1н-бензимидазол
ES2150577T3 (es) Aminoeteres aromaticos como agentes para aliviar el dolor.
ES541521A0 (es) Un procedimiento para la preparacion de piridazinaminas.
ES2185711T3 (es) 1,4-benzotiazepina-1,1-dioxidoshipolipimemicos.
ES2031876T3 (es) Un procedimiento para la preparacion de 5,6-dihidro-2-(fenil sustituido)-1,2,4,-triazin-3,5(2h,4h)-dionas.
ES2063011T3 (es) Agentes antibacteriales de quinolonas y naftiridinas que contienen un alfa-aminoacido en la cadena lateral del 7-sustituyente.
ES2037681T3 (es) Procedimiento para preparar nuevos estirilpirazoles, isoxazoles y analogos de los mismos que tienen actividad como inhibidores de 5-lipoxigenasa.
ES2040727T3 (es) Un proceso para preparar una formulacion en aerosol en solucion de un analogo.
MX7012A (es) Procedimiento para preparar derivados de acido-cis,endo-2-azabiciclo-(5.3.0.)-decan-3-carboxilico.
ES2063033T3 (es) Empleo de igf-ii en el tratamiento de la enfermedades de los huesos.
MX9300407A (es) Derivados azabiciclicos usados en la fabricacion de medicamentos, composiciones que los contienen y procedimiento para su preparacion.
ES2059489T3 (es) Derivados bencimidazol 1-alkil sustituidos.
ES2129485T3 (es) Derivados de acidos guanidinoalquil-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion.
ATE72238T1 (de) Imidazoliumsalze, zwischenprodukte fuer ihre herstellung sowie ihre verwendung.
MX168030B (es) Procedimiento para la preparacion de derivados de alcano y alcoxialcano
ES2062664T3 (es) Poli(acido alfa-hidroxilacrilico) y derivados como compuestos activos antisarro en composiciones orales.
DK0750616T3 (da) Syreadditionssalte af 2,3,4,5-tetrahydro-1H-3-benzazapinforbindelser
ES2037709T3 (es) Derivados heterociclicos de seis miembros de n,n'-diacilhidrazinas n'-sustituidas.
ES2145234T3 (es) Derivados de la diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2086528T3 (es) Nuevos compuestos biciclicos sustituidos con amino.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 260236

Country of ref document: ES